Sarepta’s Elevidys: Evidence For Micro-Dystrophin Surrogate Endpoint In Young Patients Insufficient, FDA Reviewers Said

 
• By Sue Sutter
Overruled
The Elevidys application review committee called for a complete response letter, but the recommendation was overridden by CBER's Peter Marks. • Source: Shutterstock

More from Approvals

More from Product Reviews